SUVN G3031

Drug Profile

SUVN G3031

Alternative Names: SUVN-G3031

Latest Information Update: 31 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Suven Life Sciences
  • Class Neuropsychotherapeutics; Nootropics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders
  • No development reported Parkinson's disease

Most Recent Events

  • 01 Aug 2016 Suven Life Sciences initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02881294)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in India (PO)
  • 12 Jul 2016 Suven Life Sciences has patent protection for SUVN G3031 in India and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top